Component

Human fasting insulin-resistance indices in the 2016 carnosine pilot

Context-specific entity; species, compartment and exposure are stated on each claim.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Carnosine supplementation attenuated the rise in fasting insulin and insulin-resistance indices relative to placebo.

    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Thirty overweight/obese adults; 2 g/day for twelve weeks.
    limitations
    Pilot outcomes do not establish diabetes prevention; linked carbonyl paper may use the same trial.
    nutrient_topic
    Carnosine collection; isomer, preparation, species, exposure and manipulation remain explicit. · L-Carnosine / beta-alanyl-L-histidine
    plain_language
    A small human trial reported a metabolic signal.
    primary_references
    Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 · https://pubmed.ncbi.nlm.nih.gov/27040154/ · DOI 10.1002/oby.21434

    Carnosine: synthesis, transport, carbonyl chemistry and nutrient interactions (2026-09-19) · lines 484–490

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Thirty overweight/obese adults; 2 g/day for twelve weeks. · source_derived_draft · unverified_draft

    ## carnosine-pilot-insulin A small human trial reported a metabolic signal. Carnosine supplementation attenuated the rise in fasting insulin and insulin-resistance indices relative to placebo. Model: Thirty overweight/obese adults; 2 g/day for twelve weeks. Limitations: Pilot outcomes do not establish diabetes prevention; linked carbonyl paper may use the same trial. Evidence access: Primary abstract Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial. · 2016 · https://pubmed.ncbi.nlm.nih.gov/27040154/ · DOI 10.1002/oby.21434
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards